Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report by Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

“…New agents, including zongertinib, a HER2-selective tyrosine kinase inhibitor (TKI), are being investigated in clinical trials. …”
Get full text

Constitutive activation of the Src-family kinases Fgr and Hck enhances the tumor burden of acute myeloid leukemia cells in immunocompromised mice by Sherry T. Shu, Li Chen, Giancarlo Gonzalez-Areizaga, Thomas E. Smithgall

“…To induce constitutive kinase activity, Hck and Fgr were fused to the coiled-coil (CC) oligomerization domain of the breakpoint cluster region protein associated with the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. Expression of CC-Hck or CC-Fgr transformed TF-1 cells to a granulocyte–macrophage colony-stimulating factor (GM-CSF)-independent phenotype that correlated with enhanced phosphorylation of the kinase domain activation loop. …”
Get full text

Expression and significance of CEMIP and CYP11B2 in serum in women with foetal growth restriction by Yang Yue, Fang Fang Zhou, Jia Rong Zhang, Fu Xu

“…CEMIP (95%CI: 0.802–0.921, P < 0.001) and CYP11B2 (95%CI: 0.795–0.907, P < 0.001) mRNA expression in serum and soluble fms like tyrosine kinase-1 (sFLT1)/placental growth factor (PlGF) ratio (95%CI: 0.866–0.974, P < 0.001) were independent predictors of FGR, and CEMIP (r = −0.578, P = 0.001) and CYP11B2 (r = −0.602, P < 0.001) mRNA expression in serum were negatively correlated with sFLT1/PlGF ratio. …”
Get full text

Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study by Geke Zhu, Han Zhou, Wanying Wang, Yongbo Ma, Xiangtao Nie, Wenjing Qi, Lei Hao, Xiuming Guo

“…During the 8-week follow-up, in GMG patients, whether positive for acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) antibodies, the overall efficacy was significant. …”
Get full text

Pharmacovigilance imbalance analysis of VEGFR-TKI-related taste and smell disorders by Zhong-hua Fu, Chenglong Zhao, Yaqin Wang, Lei Zhang, Lei Wang

“…The advent of targeted drugs such as vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) has significantly extended the survival time of cancer patients, and thus widely used in clinical practice. …”
Get full text

Magnetic Resonance Imaging Combined with Serological Markers Improves the Diagnosis of Placenta Previa with Placenta Accreta Spectrum by Ying Wang, Zhengdong Hou, Bingqing Xia, Xianjing Xie, Ying He

“…The aim of this study was to evaluate the accuracy of magnetic resonance imaging (MRI) combined with three serological markers (alpha-fetoprotein [AFP], creatine kinase [CK], and soluble fms-like tyrosine kinase-1 [sFlt-1]) for the diagnosis of PP with PAS. …”
Get full text

Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma by Yuji Uehara, MD, Hiroki Izumi, MD, PhD, Tetsuro Taki, MD, PhD, Tetsuya Sakai, MD, PhD, Hibiki Udagawa, MD, PhD, Eri Sugiyama, MD, PhD, Shigeki Umemura, MD, PhD, Yoshitaka Zenke, MD, PhD, Shingo Matsumoto, MD, PhD, Kiyotaka Yoh, MD, PhD, Shoko Kubota, MD, PhD, Keiju Aokage, MD, PhD, Naoya Sakamoto, MD, PhD, Shingo Sakashita, MD, PhD, Motohiro Kojima, MD, PhD, Michiko Nagamine, MD, PhD, Yukio Hosomi, MD, PhD, Masahiro Tsuboi, MD, PhD, Koichi Goto, MD, PhD, Genichiro Ishii, MD, PhD

“…Introduction: Resistance to EGFR tyrosine kinase inhibitors is influenced by tumor-intrinsic and -extrinsic factors. …”
Get full text

Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma by Chuyu He, Xuejuan Wang, Yi-Shiou Chiou, Basappa Basappa, Tao Zhu, Vijay Pandey, Peter E. Lobie

“…Furthermore, a high-throughput combinatorial anti-cancer compound library screening revealed that AMPC preferentially synergized with receptor tyrosine kinase c-MET inhibitors (c-METis) to reduce cell survival and the CSC-like phenotype. …”
Get full text

Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection by Song Dong, PhD, Bingfa Yan, PhD, Si-Yang Liu, PhD, Xuan Gao, PhD, Hui-Zhao Hong, MD, Hong-Ji Li, MD, Wei Gao, PhD, Hong-Hong Yan, PhD, Si-Yang Maggie Liu, PhD, Hai-Yan Tu, PhD, Yi Pan, PhD, Qing Zhou, PhD, Xue-Ning Yang, PhD, Xue-Feng Xia, PhD, Xin Yi, PhD, Wen-Zhao Zhong, PhD, Yi-Long Wu, MD, Jia-Tao Zhang, PhD

“…Introduction: EGFR tyrosine kinase inhibitor (TKI) is the standard adjuvant treatment for patients with stages IB to IIIA EGFR-mutated NSCLC. …”
Get full text

Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor by Baojie Liu, Yongzheng Lu, Ruihui Lin, Junbao Xu, Zilin Shang, Xinyu Hou, Xulong Shao, Zhifang Pan, Tao Yu, Weiguo Feng

“…As a result, it is crucial to discover effective medications against ABCB1 to overcome MDR. Falnidamol, a tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR), is currently in phase 1 clinical trials for the treatment of solid tumors. …”
Get full text

Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma by Zhaosong Xue, Ming Yao, Kang Chen, Taiyun Huang, Jianjun Li, Jian Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan

“…Abstract  Combining local interventions with tyrosine kinase inhibitors (TKIs) plus anti-PD-1 antibodies in a triple therapy has demonstrated remarkable anti-tumor efficacy and facilitated conversion resection in patients with initially unresectable hepatocellular carcinoma (HCC). …”
Get full text

Possibility of Using NO Modulators for Pharmacocorrection of Endothelial Dysfunction After Prenatal Hypoxia by Igor Belenichev, Olena Popazova, Oleh Yadlovskyi, Nina Bukhtiyarova, Victor Ryzhenko, Sergii Pavlov, Valentyn Oksenych, Oleksandr Kamyshnyi

“…Levels of sEPCR, Tie2 tyrosine kinase, VEGF-B, SOD1/Cu-Zn SOD, GPX4, and GPX1 in the heart’s cytosolic homogenate were assessed using ELISA. …”
Get full text

Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report by Meng LU, Ran ZHANG, Baiwei LI, Haidi XU, Yongkuan GUO, Jian YOU, Bingsheng SUN

“…For advanced NSCLC with METex14m, Savolitinib has a high sensitivity as a member of tyrosine kinase inhibitors (TKIs). METamp is a relatively rare genetic mutation type which can serve as a driver gene to mediate primary and later acquired drug resistance of epidermal growth factor receptor (EGFR)-TKIs. …”
Get full text

The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis by Shiwei Liu, Miao Yu, Exian Mou, Meihua Wang, Shuanghua Liu, Li Xia, Hui Li, Hao Tang, Yajing Feng, Xin Yu, Kun Mi, Hao Wang

“…In pCR analysis, three neoadjuvant regimens sequentially ranked at the top, namely those comprising T-DM1, pertuzumab with trastuzumab, and tyrosine kinase inhibitor with trastuzumab, demonstrating significantly higher pCR rates than monotherapies. …”
Get full text

ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2 by Dan Li, Wenjie Zhang, Ruiheng Wang, Shufeng Xie, Yixin Wang, Wanxin Guo, Zixuan Huang, Chaoqun Lu, Liang Shan, Han Liu, Lifang Ma, Xumin Hou, Zhenshu Xu, Jiayi Wang

“…This study investigated the potential of combining receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeting CAR-T cells with ferroptosis inducers to promote ferroptosis of tumor cells and enhance anti-tumor efficacy. …”
Get full text

Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective by Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin

“…**Background:** Tyrosine kinase inhibitors (TKIs) are the standard-of-care treatment for chronic myeloid leukemia in chronic phase (CML-CP). …”
Get full text

Novel genes involved in vascular dysfunction of the middle temporal gyrus in Alzheimer’s disease: transcriptomics combined with machine learning analysis by Meiling Wang, Aojie He, Yubing Kang, Zhaojun Wang, Yahui He, Kahleong Lim, Chengwu Zhang, Li Lu

“…Two subtypes of middle temporal gyrus cells showed significant alteration in AD: endothelial cells with high expression of Erb-B2 receptor tyrosine kinase 4 (ERBB4high) and pericytes with high expression of angiopoietin-like 4 (ANGPTL4high). …”
Get full text

Epigenetics of suicidal behavior by R. N. Mustafin, A. V. Kazantseva, R. F. Enikeeva, Yu. D. Davydova, S. B. Malykh, V. V. Viktorov, E. K. Khusnutdinova

“…The analysis of a brain obtained from suicide victims, representing a unique tool for the analysis of modified genomic processes, revealed a wide range of reprogramming patterns of DNA methylation in promoters of the genes of polyamine (OAZ1, OAZ2, AMD1, ARG2, SKA2), serotonergic (SLC6A4) and GABAergic (GABRA1) systems, HPA-axis (GR, NR3C1), tyrosine kinase (TrkB) receptors, brain-derived neurotrophic factor (BDNF). …”
Get full text

Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial by Christopher J. Swearingen, Jeyanesh R. S. Tambiah, Ismail Simsek, Heli Ghandehari, Sarah Kennedy, Yusuf Yazici

“…Abstract Introduction Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. …”
Get full text

Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors by Guihong Yang, Yimei Wang, Huimin Zhao, Ziyi Jiang, Shansong Zheng, Mingjing Ge, Meimei Si, Xiaoyan Kang

“…Abstract Iruplinalkib (WX‐0593), a selective oral ALK/ROS1 tyrosine kinase inhibitor, was approved in China as first‐line therapy for ALK‐positive non‐small‐cell lung cancer (NSCLC) and for the treatment of locally advanced or metastatic ALK‐positive NSCLC that has progressed following crizotinib therapy. …”
Get full text